

# Biopharmaceutical Tier-2 Diagnostic Tools for Chronic Neuropenia and Osteoporosis: A New Approach to Aerospace Medicine

V Lunde Dadon<sup>1\*</sup>, V Lyinda Dadiyane<sup>2</sup>, Vivian Wolfsson<sup>3</sup> and Simone Bridgsson<sup>4</sup>

<sup>1</sup>Oak Ridge Aerospace Institute DOE, DPO Outlying Islands

<sup>2</sup>Fleet Ecology Institute on Metallurgic Studies, DPO Outlying Island

<sup>3</sup>Lofton Epigenetics Laboratories, DPO Outlying Islands, Jan Mayen Svalbaard

<sup>4</sup>Bio\_RAD and Bio\_MED Research Center Artic Circle, DPO, Bouvet Islands

\*Corresponding author: V Lunde Dadon, Oak Ridge Aerospace Institute DOE, DPO Outlying Islands.

E-mail: [mllcsage808@gmail.com](mailto:mllcsage808@gmail.com)

**Received:** August 14, 2024; **Accepted:** August 27, 2024; **Published:** September 15, 2024

## Introduction

Biopharmaceutical Industry has introduced a new method to treat Chronic Neutropenia, and Osteoporosis by the treatment call AeroPharma. This is a New Approach to Biopharmaceutical in the field of Aerospace, AeroFlights Operations, and hyperbaric chambers. In this case study will take deep dive into the process of simulation of the peptides from B. Subtillis, as it provides two tier of secreted hormones used in the treatment of Aerospace Medical Cases, such as catalyst hormone in Teraparatide and Filgrastism. Our staff worked very diligently in generating 2-Tier Reports Classifiable Drugs, the sequencing of the phases of initiation of treatment, Regional Drug Compliance, and treatment, and outcomes.

+Med Kits were issued in Aeronautical Societies, for one reason, they include supplies of painkillers, antibiotics, antiemetics, etc. (Medical Checklist, 2006). Our Institute hopes to provide more preventative care in ISS medical emergency units, and training so that the mission and the crew don't return to Earth for operational issues. However, the consideration of pharmaceutical availability becomes even more important for the multi-year missions that will be required for Mars, and the Moon, as speedy re-supply and/or evacuation missions are not possible. Reliance on pharmaceuticals is particularly important in Space Exploration and for Cabin Crews. And so we collaborated and tasked our Research and Development Unit properly with safety equipment.

**Keywords:** Teriparatide; Filgrastism; Aerospace medicine; Aeropharmacy; Diagnostic tools and reports; Research and testing; Clinical case study; Microgravity; Microcell spores; ICD diagnostic tools; Pharmacy; Hospital pharmacy

**Methods to use of Pharmaceuticals in Aerospace Medicine Cases**

1a. Teraparotide and Filgrastim was introduced in the mission after being inoculated from B. Subtillis. The secretion from B. Subtillis (aerobic bacterium catalase-positive bacterium) produced a peptide to used in the Clinical Trials Filgarastim and Teraparotide for Aerospace Medical Treatments of Neuropenia, and Risk of Osteoporosis by a Medical Doctor.

1b. The phases were set in a diagram for Conceptual Design of the approach, and tables, with discussion and observation of the phases of control field testing with our Pathologist in approved FDA-DEA laboratory.





Figure (1) In this Diagram we present the (RBS) and Teraparotide, and illustrate the post-production of the B. Subtillis into the pAVE 147 and pAVE 148 ~.

2a. The patients presented with symptoms of fatigue, overexposure to Radiation, and decreased Sport Mobility, and Musculoskeletal anomalies.

2b. We began a 2nd Phase of Cyclical Testing for the B. Subtillis, found in soil, mines, and metallurgic substances, so then used



ddPCR through our own laboratories to monitor and control the secretions of the hormone and chartered the data with similar BioPharmaceuticals Reports. {1}


Figure (2) Diagram shows the plasma-vector phase and transformation of microbial cell biofilm, and cyclical culture into colony, stimulation of the colony then adheres to production of the synthetic hormone use in Teraparotide ml/mcg and Filgrastim 300 mcq (intravenous). The secretion thus produces a positive bacterium needed for Aerobiology of the treatment of co-morbidity. {2}

3a. Antimicrobial compounds used in this research, were the milestones in MicroCell Colony Stimulation. Once the Colony was organically phased into a diagram, we adhered to the Compound Pharmaceutical Treatment with the intravenous Filgrastim 300 mcg and Teraparotide ml/mcg suspended (IV). {1}{2}

3b. In the diagram we show the phases, and the cyclical data with the climate control mechanisms for compound pharmaceuticals in controlling this Clinical Trial. {3}

4a. The conditions were meet remarkable but comparable climate control, one room was set at Room Temperature 76 ‘ Celsius and the other Cabin Hyberbaric Temperature at 78’ Celsius. {1}{3}

Figure (3): The table here shows the room temperature comparable to Hyberbaric Chamber in Space Shuttles, to Airline Cabin



Crew. pAVE 147 ~ and pAVE 148~.

4b. The MicroGravity, physiological implications to exposure to the hyberbaric environment was measured and chartered in Research and Development Criteria, and reported in a our Medline Plus Survey Results, and Bio Engineering for Hospital Pharmacy Survey. {1}

### Experiments on Clinical Case Study

<1 The phases of the simulation to organic adjunct peptides and hormones we diagrammed and tested; the drug was administered during treatment and produced a wide set of standards in new Aerospace Medicine 2024-2050.

<2 We found that during the treatment and survey we issued had to segregate certain data sets based on budget, climate control, single occupancy of unit. The Astronauts was in orbit for 6 years, versus the Airline Pilot that had intervals of long stays in hyberbaric chambers. So the the Clinical case had to be assigned a two tier Clinical Trial for Research and Treatment, under Grant ERA-POC-2020. {3}

<3 As we continued our research our results were remarkable after completed a gel stains ddPCR, PET/MRI, PET/CT and MicroCell Laboratory Stains (RBS). Inoculations, and administration Teraparadine and Filgrastism (intravenous) with protocols produced an equilibrium in the immune features to prevent neuropenia with the stimulation for production of functions for blood cells, and the adherence to controlling the risk of osteosporosis with synthetic hormone. {2}{1}

<4 B. Subtillis was the catalyst to produce synthetic hormones for control of risk of low neutrophils, and osteoporosis. It was used in the applications of adaptable metabolism of protein secretions. This covers biofilm 550 ddPCR and 43.3.04 Microbial Applications.

<5 Classical Counter Selection Bio-Markers were developed to biofilm the (RBS) Ribosomal binding site (ribbon), placed in a based tool box. {1}{2}{3}

### **Conclusions and Summary**

We saw in this Clinical Case the psychological stress, the chronic diagnosis of neuropenia, and the risk of osteoporosis, during Clinical Trials and 2nd Regional Reports Index. Our Physicians safely stored the Med Kits for preservation and conservation of resources.

We adhered to these standards to produce this article to enhance your awareness on the co-morbidities of chronic neuropenia, and risk of osteoporosis in the Diagnostic Criteria to Occupations in the Aerospace Field and Fleet Flight Control Operations, specifically Astronauts, Reservists, Airline pilots, Cabin Crew, Flight Operations Units.

Nevertheless, we strive to provide the newest innovations through our Lofton Epigenetics Laboratories by creating in depth research into vital, and resilient approaches to treating conditions in specialized fields like Aerospace Medicine, and Occupational Health.

### **Declaration of Conflict of Interest**

We don't not work with the United States, or populations or IC3. We are a Sole Proprietorship, and only work with Clinical Cases and Material Science and no guarantee for rights outside of publishing clearinghouse.

### **Acknowledgements**

Dr. V Lunde Dadon, MD, Dr. V Lyinda Dadiane MD, Dr Vivian Wolfsson PhD. Contributing Clinical Case Studies, and Clinical Review for Pharmacy, Metallurgic Pathologist Dr Simone Bridgesson (Multifaceted and Honorary Researcher), IHG (Island Health Group, Beneficial Owner under Participant Registry 876298292 EU Funding/Grants Horizon2020), Aerospace Medicine and Prescribing Tools for Hospital Pharmacists, Codex System for Pulmonology and Neurology, and Immunotherapy. Creative Labs Futopia International Space X Designs. Affiliate partners International Nuclear Research L.P, Also acknowledgement to our Laboratory associate for putting together a Internal Medicine Chartered Diagrams, for comparable diagnostics criteria for Flight Operators in Space and in Airline Terminals.

### **REFERENCES**

1. Royal Aeronautical Society: Careers and Education. Advancing the Future of Aerospace. DOI/<https://www.aerosociety.com/get-involved-specialistgroups-safety-aerospacemedicine.com>. 20224
2. Drugs GoodRX. Teriparatide. A603018. Forsteo. AHFS. WHO\_Essential Drugs (FDA\_DEA) 1996-2024 Cerner Multum. Version 3.02. 1999.
3. Drugs GoodRx. Filgrastim. A692033. Neupogen. Granulocyte Colony- Stimulation AHFS. WHO\_ Essential Drugs (FDA-DEA) 1996-2024.

4. Grant European Space Aerodynamics. DD-SSA-VA-21-529EZ. 1991 (1053-T749). Art. 4F3B4-9ENF. 2006. Et al. NASA 2013. Participants Registrations ID: 876298292. 2013.
5. Sports Medicine: Extreme Enclosed Spaces for Training, and Endurance. 2013. Art. 61-77. SE33. NPA. Neuropathological for Extreme Endurance Sessions.
6. SPIE Photonics and Optics in Laboratory Science. Published by Lofton Epigenetics Laboratories. ddPCR 2024-2030. Conceptual Design in Photonics for PCR Data tool boxes and applications. Art. SE33. NPA. 43-99. 61-77. 85-90. 2024.
7. Journal of Aerobiology. MDPI. Bio Engineering of Synthetic Hormones for Sustainable Environments containing Hyberbaric Chambers. Art. 221-316. Pg.112.
8. Journal of Internal Medicine. MDPI. Hospital Pharmacy Occupational Medicine. Art. 22. Art. 33. Pg 102-110.2009